Does cyber insurance respond to an OCR HIPAA enforcement action when there was no breach?

Coverage summaries across the industry, including elsewhere on this site, routinely list regulatory defense for HHS Office for Civil Rights proceedings as a cyber policy feature. That is accurate as far as it goes, and it can create a reasonable but incomplete impression that any OCR matter is covered.

The precise question is not whether the policy contemplates OCR. It is what has to happen before the policy responds at all. Coverage grants attach to a defined trigger, and if the trigger is an event involving compromised information, an enforcement action about paperwork may sit outside it.

A significant share of enforcement is not about a dramatic intrusion. Recurring themes include the failure to conduct an accurate and thorough risk analysis across the organisation, missing or unexecuted business associate agreements, failure to provide individuals timely access to their own records, and inadequate policies, procedures, or workforce training.

Several of those categories can be established without any unauthorised access to protected health information ever occurring. An investigation can also begin from a patient complaint or a compliance review rather than from a reported breach.

Read the trigger language in the regulatory defense and penalties agreement rather than the marketing summary of it. The useful distinction is between an agreement that responds to a regulatory proceeding arising from a privacy or security event, and one that responds to a regulatory proceeding arising from an actual or alleged violation of a privacy regulation.

The second is materially broader, because it does not require an event to have occurred. Where a policy uses the narrower construction, an access-rights or risk-analysis matter may not attach, and that is the scenario to test with your broker in writing.

Penalties themselves carry the usual limitation: insurable only where law permits. Defense costs are the more dependable component of the agreement in any construction.

This is not an unfamiliar problem in life sciences. An FDA Form 483 observation or a warning letter is a regulatory finding, and the question of whether any policy funds the response to it is one operators in this sector already understand.

Treat OCR the same way. Ask which policy pays for counsel, which pays for the technical remediation the resolution agreement will require, and whether a corrective action plan running for years creates costs nobody has budgeted.

Ask your broker one specific question and keep the answer: does the regulatory agreement respond to an OCR investigation opened without any breach of protected health information, for example one arising from a risk-analysis deficiency or an individual access complaint.

If the answer is no or is qualified, that is a wording negotiation at renewal rather than an emergency. It is a far better conversation to have then than during an investigation.